NCT00925275已完成1 期
A Phase I, Multi-Center, Open-Label, Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors Who Have Failed Standard Therapy or for Whom No Standard Therapy Exists
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 4
- 主要终点
- Calculate whole body and organ radiation dosimetry of I-131-CLR1404 to determine the millicurie dose which is expected to deliver 35-40 centigray of radiation to bone marrow
研究概览
简要总结
The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of I-131-CLR1404.
详细描述
I-131-CLR1404 is a small-molecule, phospholipid ether analog that combines lipid-like properties with a cancer therapeutic beta-emitting radioisotope. Cellectar believes that this compound will benefit individuals with cancer due to its selective retention and accumulation in malignant cells versus nonmalignant cells. Preclinical experiments have demonstrated that I-131-CLR1404 significantly slows malignant tumor growth in several mouse tumor models.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Relapsed or refractory advanced solid tumor(s) and have exhausted standard treatment options or no standard therapy exists
- •Must have a sufficient window of time to complete the washout period, dosimetry data acquisition and the follow up safety assessment period
- •ECOG performance status of 0 or 1 and estimated life expectancy of ≥ 4 months
- •18 years or older
- •Must be compliant with the protocol and be within geographical proximity to make the required study visits
- •Have the ability to read, understand and provide written informed consent
- •Patients with brain metastasis are acceptable if the clinical condition has been stable for at least one month
- •Female patients of childbearing potential must have a negative serum pregnancy test within 24 hours of start of treatment
- •Must agree to use an effective method of contraception during the study and for 90 days following the last dose of study drug
排除标准
- •Patient or physician plans concomitant chemotherapy, therapeutic radiation treatment, and/or biological treatment for cancer including immunotherapy while on study
- •More than 25% of the total bone marrow irradiated
- •Diffuse lung disease or interstitial spread of carcinoma
- •Bladder or rectum is within a prior radiation therapy field and a dose of greater than 45 Gy was administered
- •Total therapeutic radiation dose in the past year in excess of 25 Gy to the kidney, 45 Gy to brain, 45 Gy to stomach, 18 Gy to lung, or 25 Gy to liver
- •Prior total-body irradiation
- •Extradural tumor in contact with the spinal cord, or tumor located where swelling in response to therapy may impinge upon the spinal cord
- •Prior radiation therapy or chemotherapy within 2 weeks of the start of the study
- •Active medical condition(s) or organ disease(s) that may either compromise patient safety or interfere with the safety and/or outcome evaluation of the study drug
- •Laboratory values ≤ 7 days:
- •WBC < 3000/µL
- •Absolute neutrophil count < 1500/µL
- •Platelets < 150,000/µL
- •Hemoglobin ≤ 11.0 gm/dL
- •Total bilirubin > 1.5 x upper limit of normal for age
- •SGOT or SGPT > 3 x upper limit of normal for age if no liver metastases or > 5 x upper limit of normal for age in the presence of liver metastases
- •Serum creatinine > 1.5 x upper limit of normal for age
- •INR ≥ 2.0
- •Investigational drug, investigational biologic, or investigational therapeutic device within 30 days of initiating study drug
- •Severely marrow toxic drugs (e.g. nitrosoureas, mitomycin)
- •Prior treatment with Iodine-131 in the past five years
- •Concurrent hemodialysis
- •Blood transfusions within 60 days of study start
- •Hematopoietic growth factor therapy within 60 days of study start
- •Prior stem cell transplantation
- •Clinically evident ascites or with peritoneal carcinomatosis
- •Clinically significant cardiac co-morbidities including: CHF, a LVEF< 40%, unstable angina pectoris, serious cardiac arrhythmia requiring medication or a pacemaker, myocardial infarction within the past six months
- •Clinically significant pulmonary impairment defined as an SaO2 on room air of 93% or less
- •Concurrent or recent use of thrombolytic agents, or full-dose anticoagulants
- •Uncontrolled hypertension or patients with uncontrolled diabetes
- •Grade II-IV peripheral vascular disease or peripheral vascular surgery within the past year
- •Less than 4 weeks since prior major surgery
- •Known positive for HIV, Hepatitis C (active, previously treated or both), or is Hepatitis B core antigen positive
- •Concurrent chronic use of aspirin (325 mg/day or more)
- •Pregnant or lactating
- •Patients with colostomy/ileostomy
- •Poor venous access
- •Prior allergic reactions to iodine, or other study agents
- •Significant traumatic injury within the past 4 weeks
- •Ongoing or active infection requiring antibiotics or with a fever >38.1°C (>101° F) within 3 days of the first scheduled day of dosing
- •Patients who are hospitalized
研究组 & 干预措施
Dosimetric
Experimental
干预措施: I-131-CLR1404 (Drug)
结局指标
主要结局
Calculate whole body and organ radiation dosimetry of I-131-CLR1404 to determine the millicurie dose which is expected to deliver 35-40 centigray of radiation to bone marrow
时间窗: 42 days
次要结局
- To determine the safety and pharmacokinetic profile of I-131-CLR1404(42 days)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the SkeletonMetastasesPharmacokineticsProstate CancerNCT00748046Bayer10
已完成
1 期
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate CancerProstate CancerNCT03995888Blue Earth Diagnostics24
已完成
1 期
PK in Pts With HRPC & Skeletal MetastesProstatic NeoplasmsNCT00667537Bayer6
终止
1 期
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate CancerProstatic NeoplasmNCT03490838Advanced Accelerator Applications27
终止
1 期
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT01464034Criterium, Inc.136